S&T technique to detect breast cancer moving from lab to commercialization
Posted by Mary Helen Stoltz
On February 2, 2016
Cancer screening could soon be as simple as giving a urine sample using a patented device developed by a Missouri University of Science and Technology researcher. This week, Wyoming-based Cancer.im Inc., a Viratech Corp. company (Symbol: VIRA) and social network for cancer patients, survivors and caretakers, announced an agreement with Missouri S&T to commercialize the device.
The device, known as a “P-scan,” is a rapid, point-of-care test for early screening of cancer that noninvasively monitors levels of pteridine biomarkers in urine. Its creator, Dr. Yinfa Ma, Curators’ Teaching Professor of chemistry at Missouri S&T, says the device is being developed to diagnose breast cancer – and determine its severity – with the hope that it may replace or supplement the mammogram. The researchers believe the diversity of these biomarkers means they also have applications in detecting other cancers.
“The mammogram is not perfect,” Ma says. “Many early cancers cannot be detected by the mammogram, while other benign tumors are falsely detected. The P-Scan technology will help alleviate this problem by using molecular biomarkers in a detection method that can be easily integrated into a routine physical screening. A patient donates urine and 10 minutes later she has a result. This will be an amazing diagnostic tool.”
The P-scan works by passing the urine through a small capillary and detecting the fluorescence given off by the pteridine biomarkers. The advantage of this technique is that it delivers excellent sensitivity without the need for costly instrumentation. The P-Scan can detect over 70 unique compounds in urine, many of which Ma believes may also be indicators of specific cancers, which he hopes to study in future clinical trials.
“Cancer cells grow much faster than normal cells,” Ma explains. “So they release more waste into the urine and we begin to see a rise in certain metabolite levels.”
Ma’s studies suggest that two of these pteridine metabolites, “isoxanthopterin” and “xanthopterin” were present in elevated levels in the urine of women with newly diagnosed breast cancer. New clinical trials are under way at Missouri S&T to verify these findings and to test whether pteridine biomarkers can be used to detect other types of cancers.
“We will go cancer by cancer until we know,” Ma says.
The National Cancer Institute estimates that over 1.6 million people will be diagnosed with cancer this year. Nearly one in eight women will develop invasive breast cancer during her lifetime. Around 85 percent of women diagnosed with breast cancer have no family history of the disease.
“I am very excited about this project,” Ma says. “It will save lives. That’s my motivation.”
Share this page
Posted by Mary Helen Stoltz
On February 2, 2016. Posted in College of Arts, Sciences, and Business, Department of Chemistry, Featured, Research, Science & Tech
Leave a Reply Cancel reply
2 thoughts on “S&T technique to detect breast cancer moving from lab to commercialization”
Looking for something?
CASB Department News
- Army ROTC Stonehenge Battalion (8)
- Department of Arts, Languages and Philosophy (214)
- Department of Biological Sciences (51)
- Department of Business and Information Technology (42)
- Department of Chemistry (77)
- Department of Economics (4)
- Department of English and Technical Communication (49)
- Department of History and Political Science (98)
- Department of Mathematics and Statistics (24)
- Department of Physics (45)
- Department of Psychology (21)
- Department of Teacher Education and Certification (10)
Recent Posts
- St. Louis entrepreneur, Square co-founder Jim McKelvey to visit Missouri S&T for “rapid fire” discussion
- Missouri S&T prepares for 111th St. Pat’s celebration
- S&T Ballet and Dance Club to perform ‘Wizard of Oz’
- Missouri S&T to host History Day contest
- Volunteers needed for robotics competition at S&T
Recent Comments
- Raymond Ernst on Missouri S&T researcher helps engineers interpret big data
- David G Sizemore on Dr. Nord Gale, founding chair of biological sciences, dies
- David G. Sizemore on Missouri S&T historian to appear in HISTORY’s ‘Presidents at War’ premiering Feb. 17
- Hamid A. on Missouri S&T students receive Grainger Power Engineering Awards
- Rhonda Gilchrist on Sharing a passion for mathematics
Upcoming events
Sports Headlines
- S&T track & field teams set to compete at GLVC Championships
- Softball Set for Lewis Dome Invitational This Weekend
- Women's Basketball Concludes Road Schedule at Maryville, Missouri-St. Louis
- S&T's Swadley named as GLVC Field Athlete of Week
- Men's basketball team closes road schedule in St. Louis this week
Categories
- News (2,287)
- Events (1,552)
- Featured (1,012)
- Top Headlines (907)
- People (848)
- Research (615)
- College of Arts, Sciences, and Business (425)
- College of Engineering and Computing (424)
I think this is a fabulous product that could save so many lives! Thanks for caring! I only hope the tests will be very inexpensive so that ALL women will be entitled!!134
A great news for humanity. Love to see its wide spread commercial use including my country, Bangladesh. Love to know further information n development.
Dr M Adnan kiber, Prof of Biomedical Engineering. EEE, Dhaka University , Bangladesh , &
Vice president 1, Bangladesh Medical Physics Association.